The National Hemophilia Foundation’s (NHF) Medical and Scientific Advisory Council (MASAC) approved a new treatment recommendation on October 29, 2005, which was subsequently adopted by the NHF Board of Directors on October 30th.

Document #165: MASAC Recommendations Concerning the Treatment of Hemophilia and Other Bleeding Disorders provides an overview of treatment options for physicians who care for patients with hemophilia, von Willebrand disease (VWD) and other bleeding disorders in the U.S. In addition, document #165 includes several tables that list all products available to treat hemophilia A and B, VWD, patients with inhibitors to factor VIII and IX and those with rare factor deficiencies. To view the document go to: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=433

To request a copy of the new recommendation contact HANDI at 800-424-2634 (option two) or handi@hemophilia.org.